LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online ; Conference proceedings: How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).

Bayon, Yves / Van Dyke, Mark / Buelher, Robert / Tubo, Ross / Bertram, Tim / Malfroy-Camine, Bernard / Rathman, Michelle / Ronfard, Vincent

Tissue engineering. Part B, Reviews

2017  Volume 23, Issue 2, Page(s) 159–162

Abstract: Regenerative medicine (RM) is a fascinating area of research and innovation. The huge potential of the field has been fairly underexploited so far. Both TERMIS-AM and TERMIS-EU Industry Committees are committed to mentoring and training young ... ...

Abstract Regenerative medicine (RM) is a fascinating area of research and innovation. The huge potential of the field has been fairly underexploited so far. Both TERMIS-AM and TERMIS-EU Industry Committees are committed to mentoring and training young entrepreneurs for more successful commercial translation of upstream research. With this objective in mind, the two entities jointly organized an industry symposium during the past TERMIS World Congress (Boston, September 8-11, 2015) and invited senior managers of the RM industry for lectures and panel discussions. One of the two sessions of the symposium-How to overcome obstacles encountered when bringing products to the commercial phase?-aimed to share the inside, real experiences of leaders from TEI Biosciences (an Integra Company), Vericel (formerly Aastrom; acquirer of Genzyme Regenerative Medicine assets), RegenMedTX (formerly Tengion), Mindset Rx, ViThera Pharmaceuticals, and L'Oreal Research & Innovation. The symposium provided practical recommendations for RM product development, for remaining critical and objective when reviewing progress, for keeping solutions simple, and for remaining relevant and persistent.
MeSH term(s) Genetic Therapy/legislation & jurisprudence ; Humans ; Intellectual Property ; Regenerative Medicine/legislation & jurisprudence ; Regenerative Medicine/methods ; Social Control, Formal ; Tissue Engineering/legislation & jurisprudence
Language English
Publishing date 2017-04
Publishing country United States
Document type Congresses
ZDB-ID 2420584-9
ISSN 1937-3376 ; 1937-3368
ISSN (online) 1937-3376
ISSN 1937-3368
DOI 10.1089/ten.TEB.2016.0292
Shelf mark
Zs.A 5500/B: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top